Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...

Maxion Therapeutics has raised £58million in a Series A finance round as it advances its KnotBody programme towards the ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Gantenerumab shows promise in preventing Alzheimers disease after past failures Gantenerumab demonstrates significant ...

Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...

A Cambridge-based biotechnology firm developing antibody-based KnotBody drugs for ion channel- and G protein-coupled receptor (GPCR)-driven diseases, has raised £58m in a Series A financing.